Fluorescent tumour imaging of type I IGF receptor in vivo

comparison of antibody-conjugated quantum dots and small-molecule fluorophore

H. Zhang, X. Zeng, Q. Li, M. Gaillard-Kelly, Carston R Wagner, Douglas Yee

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background:The type I insulin-like growth factor receptor (IGF1R) is a transmembrane tyrosine kinase involved in cancer proliferation, survival, and metastasis.Methods:In this study, we used two different fluorescent technologies (small-molecule fluorophores and quantum dot (QD) nanoparticles) to detect receptor expression and its downregulation by antibodies in vivo.Results:After conjugation with AVE-1642, a humanised anti-IGF1R monoclonal antibody, both QDs (705 nm) or Alexa 680 (small-molecule fluorophore) detected expression and downregulation of IGF1R in vitro. To examine their utility in vivo, either AVE-1642 conjugates were intravenously delivered to mice bearing xenograft tumours of mouse embryo fibroblasts expressing human IGF1R or MCF-7 human breast cancer cells. Quantum dot fluorescence was mainly localised to the reticuloendothelial system in several organs and engulfed by macrophages, with only very small amount of QDs detected in the xenograft tumours. Depletion of macrophages by clodronate liposomes did not alter the nonspecific uptake of QDs. In contrast, AVE-1642-conjugated Alexa 680 solely targeted to xenograft tumour and was able to detect IGF1R downregulation, with little nonspecific targeting to other tissues or organs in mice.Conclusion:Taken together, our data suggest that small-molecule fluorophores, not QDs, are suitable to detect the expression and downregulation of IGF1R in vivo.

Original languageEnglish (US)
Pages (from-to)71-79
Number of pages9
JournalBritish Journal of Cancer
Volume101
Issue number1
DOIs
StatePublished - Jul 7 2009

Fingerprint

Quantum Dots
IGF Type 1 Receptor
Down-Regulation
Heterografts
Antibodies
Neoplasms
Macrophages
Clodronic Acid
Mononuclear Phagocyte System
Liposomes
Protein-Tyrosine Kinases
Nanoparticles
Embryonic Structures
Fibroblasts
Fluorescence
Monoclonal Antibodies
Breast Neoplasms
Neoplasm Metastasis
Technology
Survival

Keywords

  • Antibody
  • Quantum dots
  • Small-molecule fluorophore
  • Tumour imaging
  • Type IIGF receptor

Cite this

Fluorescent tumour imaging of type I IGF receptor in vivo : comparison of antibody-conjugated quantum dots and small-molecule fluorophore. / Zhang, H.; Zeng, X.; Li, Q.; Gaillard-Kelly, M.; Wagner, Carston R; Yee, Douglas.

In: British Journal of Cancer, Vol. 101, No. 1, 07.07.2009, p. 71-79.

Research output: Contribution to journalArticle

@article{72fcba0e7bfc4186bff2e17edbb38452,
title = "Fluorescent tumour imaging of type I IGF receptor in vivo: comparison of antibody-conjugated quantum dots and small-molecule fluorophore",
abstract = "Background:The type I insulin-like growth factor receptor (IGF1R) is a transmembrane tyrosine kinase involved in cancer proliferation, survival, and metastasis.Methods:In this study, we used two different fluorescent technologies (small-molecule fluorophores and quantum dot (QD) nanoparticles) to detect receptor expression and its downregulation by antibodies in vivo.Results:After conjugation with AVE-1642, a humanised anti-IGF1R monoclonal antibody, both QDs (705 nm) or Alexa 680 (small-molecule fluorophore) detected expression and downregulation of IGF1R in vitro. To examine their utility in vivo, either AVE-1642 conjugates were intravenously delivered to mice bearing xenograft tumours of mouse embryo fibroblasts expressing human IGF1R or MCF-7 human breast cancer cells. Quantum dot fluorescence was mainly localised to the reticuloendothelial system in several organs and engulfed by macrophages, with only very small amount of QDs detected in the xenograft tumours. Depletion of macrophages by clodronate liposomes did not alter the nonspecific uptake of QDs. In contrast, AVE-1642-conjugated Alexa 680 solely targeted to xenograft tumour and was able to detect IGF1R downregulation, with little nonspecific targeting to other tissues or organs in mice.Conclusion:Taken together, our data suggest that small-molecule fluorophores, not QDs, are suitable to detect the expression and downregulation of IGF1R in vivo.",
keywords = "Antibody, Quantum dots, Small-molecule fluorophore, Tumour imaging, Type IIGF receptor",
author = "H. Zhang and X. Zeng and Q. Li and M. Gaillard-Kelly and Wagner, {Carston R} and Douglas Yee",
year = "2009",
month = "7",
day = "7",
doi = "10.1038/sj.bjc.6605103",
language = "English (US)",
volume = "101",
pages = "71--79",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Fluorescent tumour imaging of type I IGF receptor in vivo

T2 - comparison of antibody-conjugated quantum dots and small-molecule fluorophore

AU - Zhang, H.

AU - Zeng, X.

AU - Li, Q.

AU - Gaillard-Kelly, M.

AU - Wagner, Carston R

AU - Yee, Douglas

PY - 2009/7/7

Y1 - 2009/7/7

N2 - Background:The type I insulin-like growth factor receptor (IGF1R) is a transmembrane tyrosine kinase involved in cancer proliferation, survival, and metastasis.Methods:In this study, we used two different fluorescent technologies (small-molecule fluorophores and quantum dot (QD) nanoparticles) to detect receptor expression and its downregulation by antibodies in vivo.Results:After conjugation with AVE-1642, a humanised anti-IGF1R monoclonal antibody, both QDs (705 nm) or Alexa 680 (small-molecule fluorophore) detected expression and downregulation of IGF1R in vitro. To examine their utility in vivo, either AVE-1642 conjugates were intravenously delivered to mice bearing xenograft tumours of mouse embryo fibroblasts expressing human IGF1R or MCF-7 human breast cancer cells. Quantum dot fluorescence was mainly localised to the reticuloendothelial system in several organs and engulfed by macrophages, with only very small amount of QDs detected in the xenograft tumours. Depletion of macrophages by clodronate liposomes did not alter the nonspecific uptake of QDs. In contrast, AVE-1642-conjugated Alexa 680 solely targeted to xenograft tumour and was able to detect IGF1R downregulation, with little nonspecific targeting to other tissues or organs in mice.Conclusion:Taken together, our data suggest that small-molecule fluorophores, not QDs, are suitable to detect the expression and downregulation of IGF1R in vivo.

AB - Background:The type I insulin-like growth factor receptor (IGF1R) is a transmembrane tyrosine kinase involved in cancer proliferation, survival, and metastasis.Methods:In this study, we used two different fluorescent technologies (small-molecule fluorophores and quantum dot (QD) nanoparticles) to detect receptor expression and its downregulation by antibodies in vivo.Results:After conjugation with AVE-1642, a humanised anti-IGF1R monoclonal antibody, both QDs (705 nm) or Alexa 680 (small-molecule fluorophore) detected expression and downregulation of IGF1R in vitro. To examine their utility in vivo, either AVE-1642 conjugates were intravenously delivered to mice bearing xenograft tumours of mouse embryo fibroblasts expressing human IGF1R or MCF-7 human breast cancer cells. Quantum dot fluorescence was mainly localised to the reticuloendothelial system in several organs and engulfed by macrophages, with only very small amount of QDs detected in the xenograft tumours. Depletion of macrophages by clodronate liposomes did not alter the nonspecific uptake of QDs. In contrast, AVE-1642-conjugated Alexa 680 solely targeted to xenograft tumour and was able to detect IGF1R downregulation, with little nonspecific targeting to other tissues or organs in mice.Conclusion:Taken together, our data suggest that small-molecule fluorophores, not QDs, are suitable to detect the expression and downregulation of IGF1R in vivo.

KW - Antibody

KW - Quantum dots

KW - Small-molecule fluorophore

KW - Tumour imaging

KW - Type IIGF receptor

UR - http://www.scopus.com/inward/record.url?scp=67649876262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649876262&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605103

DO - 10.1038/sj.bjc.6605103

M3 - Article

VL - 101

SP - 71

EP - 79

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -